Xilio Therapeutics reports third quarter 2026 financial results

XLO•2026-11-10

Xilio Therapeutics reported third-quarter 2026 financial results and said it plans to report initial Phase 1 data for XTX501 in metastatic NSCLC in the fourth quarter of 2027.

1. Pipeline update

Xilio Therapeutics said it plans to report initial Phase 1 data for XTX501 in metastatic NSCLC in the fourth quarter of 2027.

Xilio Therapeutics reports third quarter 2026 financial results

1. Pipeline update

Related News

The TJX Companies: UBS cuts target price to $184 from $198

AST SpaceMobile: B. Riley cuts target price to $48 from $65

Centerspace: UBS raises target price to $68 from $65

Johnson & Johnson’s Caplyta reduces bipolar mania symptoms in second Phase 3 trial

MDA Space says eight Globalstar satellites pass initial on-orbit tests